NEW YORK – An artificial intelligence-powered algorithm appears to be comparable to human pathologists for scoring PD-L1 expression on tumor and immune cells for predicting immunotherapy response, a new analysis has shown.
The data, which researchers from Bristol-Myers Squibb and PathAI, a provider of AI-powered technology for use in pathology services, presented at a recent immunotherapy conference, are of interest to drugmakers looking for scalable technology solutions to accurately and reproducibly assess PD-L1.